Cardialysis and Sticares InterACT, two contract research organisations (CROs) based in the Netherlands, have announced a strategic collaboration to provide drug development services in the field of cardiovascular and metabolic medicine.

The two companies “share a common history with roots planted firmly in academia”, they say, adding that these academic origins and strong ties to cardiologists, physicians, research scientists and key opinion leaders enable Cardialysis and Sticares InterACT to offer “expert drug development services well beyond” those available from “ordinary CROs”. 

Those services are also highly complementary, the companies note, with Cardialysis excelling in core laboratory techniques, web-based clinical event adjudication, statistics, data management and clinical trial management, while Sticares InterACT’s strengths are in clinical project management, trial site management in 26 countries, medical monitoring, event management and pharmacovigilance. 

Joining forces means the two organisations “can offer complete clinical research services to our customers that combine scientific know-how with broad medical experience and outstanding execution”, said Cardialysis’ chief executive officer, Driek Vergouwen.

Cardialyis is an independent CRO focused on interventional cardiology and electrophysiology for both medical devices and pharmaceuticals. Sticares InterACT is the contract research arm of the Sticares Cardiovascular Research Institute.